The University of Oxford, in collaboration with British pharmaceutical firm AstraZeneca, has produced a leading coronavirus vaccine candidate. However, the Phase 3 clinical trial was paused because one patient is thought to have developed a serious adverse reaction. What could it be?
New research from The Scripps Research Institute in San Diego found that protective IgG antibodies, one of five major classes of antibodies, may not be the most important ones when it comes to fighting off a flu infection. This insight may help make future flu vaccines and other treatments much more effective.